Sanjeev Goswami, MD
Anesthesiology · Northampton, MANPI 1982671756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Merck at 48.8% of the total. Reporting peaked in 2019 at $238 and has fallen 56.2% since, to $105 in 2025.
Across 35 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$344
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$226
- Ipsen Biopharmaceuticals, Inc$35
- Pfizer$32
- Madrigal Pharmaceuticals$29
- Johnson & Johnson$21
- plus $19 from 1 others
What the payments were for
- Food & beverage$705100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $344 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $226 |
| Ipsen Biopharmaceuticals, Inc | 1 | $35 |
| Pfizer | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Johnson & Johnson | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
How this compares
$705 in reported general payments places this provider in the 85th percentile of 1,585 anesthesiology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,116 |
Paid to pharmacies, not to this prescriber.
Other anesthesiology in Northampton
- James StreisandCambridge$380K
- Douglas ShookBoston$267K
- Paula BokeschLexington$244K
- Robert YongBoston$231K
- Michael DambraBoston$194K
- Jasmine PatelWorcester$180K
- Robert TruogBoston$172K
- Mary Ellen McCannBoston$140K
- Stanton ShernanBoston$136K
- Edgar RossBoston$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.